Pancreatic Cancer Research

Clinical trialNAApproved for marketing

A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003

A Phase III Second Line Trial of Patients With Gemcitabine Resistant Advanced Pancreatic Cancer (CONKO-003)

NCT00786058↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Outcome unknown
Phase
NA
Status
Approved for marketing
Study type
Expanded access
Sites
0
Sponsor
Other
Results posted
No
Last update
15 June 2009

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 1